生肌象皮膏联合重组人表皮生长因子治疗下肢静脉性溃疡的效果  

Effect of Shengji Xiangpi Plaster Combined with Recombinant Human Epidermal Growth Factor in the Treatment of Venous Leg Ulcers

作　　者：王海青 WANG Haiqing(Department of Traditional Chinese Medicine Surgery,Xuzhou Hospital of Traditional Chinese Medicine,Xuzhou 221000,Jiangsu Province,China)

机构地区：[1]徐州市中医院中医外科,江苏徐州221000

出　　处：《中国实用乡村医生杂志》2024年第1期15-18,共4页Chinese Practical Journal of Rural Doctor

摘　　要：目的 探讨生肌象皮膏联合重组人表皮生长因子治疗下肢静脉性溃疡的临床效果。方法 选择2016年6月—2023年7月徐州市中医院收治的80例下肢静脉性溃疡患者作为研究对象,随机分为采用生肌象皮膏联合重组人表皮生长因子治疗的联合组,以及采用重组人表皮生长因子治疗的对照组,每组各40例。比较两组疗效、创面愈合时间和不良反应发生情况,以及治疗前后创面面积、血清炎性因子水平、生活质量。结果 治疗后,两组创面面积、血清炎性因子水平及生活质量评分较治疗前均得到改善,且联合组优于对照组,差异有统计学意义(P<0.05)。联合组临床总有效率高于对照组,差异有统计学意义(P<0.05)。联合组创面愈合时间短于对照组,差异有统计学意义(P<0.05)。两组均未发生明显不良反应。结论 生肌象皮膏联合重组人表皮生长因子治疗下肢静脉性溃疡,较单独使用重组人表皮生长因子治疗具有更好的疗效,且能够减轻炎症反应,提高患者生活质量,具有较高的安全性。Objective To explore the clinical efficacy of Shengji Xiangpi Plaster combined with recombinant human epidermal growth factor in the treatment of venous leg ulcers(VLU).Methods A total of 80 patients with VLU admitted to Xuzhou Hospital of Traditional Chinese Medicine from June 2016 to July 2023 were selected as the study subjects.They were randomly divided into a combination group treated with Shengji Xiangpi Plaster combined with recombinant human epidermal growth factor,and a control group treated with recombinant human epidermal growth factor,with 40 cases in each group.Compare the efficacy,wound healing time,and incidence of adverse reactions,as well as the wound area,serum inflammatory factor levels,quality of life before and after treatment between two groups.Results After treatment,the wound area,serum inflammatory factor levels,and the scores of quality of life in both groups improved compared to before treatment,and the combination group was significantly better than the control group(P<0.05).The total clinical effective rate of the combination group was significantly higher than that of the control group(P <0.05).The wound healing time of the combined group was significantly shorter than that of the control group(P <0.05).Both groups did not experience significant adverse reactions.Conclusion The combination of Shengji Xiangpi Plaster and recombinant human epidermal growth factor in the treatment of VLU has a better therapeutic effect than using recombinant human epidermal growth factor alone,and can reduce inflammatory reactions,improve quality of life,and have higher safety.

关 键 词：下肢静脉性溃疡 药物治疗 生肌象皮膏 重组人表皮生长因子 效果 

分 类 号：R64[医药卫生—外科学]